Prognostic impact of histopathological features and serum inflammatory markers in patients with gastric cancer undergoing neoadjuvant therapy

doi:10.4240/wjgs.v17.i6.106517

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (170)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-3)

Sum=142

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=18

Jun 27, 2025 (publication date) through Jun 2, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastrointest Surg. Jun 27, 2025; 17(6): 106517
Published online Jun 27, 2025. doi: 10.4240/wjgs.v17.i6.106517

Prognostic impact of histopathological features and serum inflammatory markers in patients with gastric cancer undergoing neoadjuvant therapy

Nilufer Bulut, Gokmen U Erdem, Tanju Kapagan, Vedat B Erol, Tunahan Sahin, Murat Yakin, Ayberk Bayramgil, Özgecan Dülgar

Nilufer Bulut, Gokmen U Erdem, Tanju Kapagan, Vedat B Erol, Tunahan Sahin, Murat Yakin, Department of Medical Oncology, Basaksehir Cam and Sakura City Hospital, Istanbul 34303, Türkiye

Ayberk Bayramgil, Özgecan Dülgar, Department of Medical Oncology, Umraniye Training and Research Hospital, Istanbul 34760, Türkiye

Author contributions: Bulut N procured data from Oncology Department of Hospital; Erdem GU, Kapagan T, Bayramgil A, and Dülgar Ö made tables, figure, and statistical analyses, and included their patients in the study; Bulut N, Erdem GU, Kapagan T, Erol VB, Sahin T, Yakin M, Bayramgil A, and Dülgar Ö have read and approved the final version of the manuscript.

Institutional review board statement: This study is approved by Basaksehir Cam and Sakura City Hospital (No. KAEK/03.04.2024.242).

Informed consent statement: There is no informed consent statement because the analysis used anonymous clinical data retrospectively.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.

Data sharing statement: The data is available upon reasonable request.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Nilufer Bulut, Associate Professor, Department of Medical Oncology, Basaksehir Cam and Sakura City Hospital, Şehir Hastanesi Cad 2L, Istanbul 34303, Türkiye. ferlut@gmail.com

Received: February 28, 2025
Revised: April 1, 2025
Accepted: May 6, 2025
Published online: June 27, 2025
Processing time: 91 Days and 19.5 Hours

Core Tip

Core Tip: Serum inflammatory markers and nutritional status influence surgical mortality. Perioperative chemotherapy contributes to survival by improving pathological response and prognosis. In addition to the tumor regression score, serum inflammatory markers, such as neutrophil, lymphocyte, platelet levels, and serum albumin levels, are used to determine prognosis. As there are no specific cut-off values for inflammatory markers reported in literature, we investigated the effect of serum levels of these markers and histopathological features on tumor prognosis.